Skip to main
FTH

FTH Stock Forecast & Price Target

FTH Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Faeth Therapeutics is in a strong position with their promising new cancer treatment, PIKTOR, which has shown early potential in reducing side effects for endometrial and breast cancer patients. The company's financial position allows for continued development until 2028, and their previous data gives them a head start in identifying the ideal dose and regimen for the drug. While facing competition, Faeth's unique dosing schedule and potential for long-term use make them a potential leader in the field, aided by positive regulatory feedback and historical data.

Bears say

Faeth Therapeutics is a clinical-stage biotechnology company with a promising drug candidate, PIKTOR, in development for endometrial and breast cancer. Despite having raised $200 million for clinical development and having a strong partner for commercialization, there is a risk of failure in the drug's development, which could negatively impact the company's financials. The expertise of the Chief Commercial Officer offers some confidence in the drug's potential, but the lengthy timeline for a top-line readout in 2026 may discourage investor sentiment.

FTH has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sensei Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sensei Biotherapeutics Inc (FTH) Forecast

Analysts have given FTH a Buy based on their latest research and market trends.

According to 7 analysts, FTH has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sensei Biotherapeutics Inc (FTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.